Targeting TLK2 inhibits the progression of gastric cancer by reprogramming amino acid metabolism through the mTOR/ASNS axis.
Wang M, Li J, Yang X, Yan Q, Wang H, Xu X, Lu Y, Li D, Wang Y, Sun R, Zhang S, Zhang Y, Zhang Z, Meng F, Li Y.
Wang M, et al. Among authors: yang x.
Cancer Gene Ther. 2023 Nov;30(11):1485-1497. doi: 10.1038/s41417-023-00653-8. Epub 2023 Aug 4.
Cancer Gene Ther. 2023.
PMID: 37542132